论文部分内容阅读
应用免疫组化ＳＰ方法检测了３３例卵巢上皮性癌、１４例卵巢上皮性良性瘤和２１例正常卵巢组织ｎｍ２３蛋白的表达，以探讨ｎｍ２３基因与卵巢上皮性癌发生、发展的关系。结果：卵巢上皮性癌ｎｍ２３蛋白阳性表达率为６９．７％，明显高于卵巢上皮性良性瘤及正常卵巢组织（Ｐ＜０．０１）；原发癌灶ｎｍ２３蛋白的阳性表达率明显高于转移灶（Ｐ＜０．０１）；Ⅰ～Ⅱ期上皮性癌患者组织中ｎｍ２３蛋白的阳性表达率明显高于Ⅲ～Ⅳ期患者（Ｐ＜０．０１）；ｎｍ２３蛋白的阳性表达与病理分级及病理分类无显著性差异（Ｐ＞０．０５）；ｎｍ２３蛋白阳性表达的患者近期疗效比阴性者好（Ｐ＜０．０５）。结果提示：ｎｍ２３蛋白阳性表达是卵巢上皮性癌的早发事件，其阳性表达率的降低预示疗效差，对卵巢上皮性癌患者进行ｎｍ２３蛋白的检测有助于判断预后。
Immunohistochemical SP method was used to detect the expression of nm23 protein in 33 cases of epithelial ovarian cancer, 14 cases of benign epithelial ovarian tumors and 21 cases of normal ovarian tissues to investigate the relationship between nm23 gene and the occurrence and development of epithelial ovarian cancer. RESULTS: The positive expression rate of nm23 protein in epithelial ovarian cancer was 69.7%, which was significantly higher than that of ovarian epithelial benign tumors and normal ovarian tissues (P<0.01). The positive rate of nm23 protein expression in primary tumors was significantly higher than that in ovarian epithelial cancers. Metastasis (P<0.01); The positive expression rate of nm23 protein in patients with stage I-II epithelial carcinoma was significantly higher than that in patients with stage III-IV (P<0.01); the positive expression and pathological grade of nm23 protein There was no significant difference in pathological classification (P>0.05). The short-term efficacy of nm23 protein positive expression was better than that of negative ones (P<0.05). The results suggest that the positive expression of nm23 protein is an early event in epithelial ovarian cancer. The decrease in the positive expression rate is predictive of poor efficacy. The detection of nm23 protein in ovarian epithelial cancer patients can help determine the prognosis.